Targeted therapy with BRAF inhibitor Vemurafenib in relapse/refractory multisystem langerhans cell-retrospective analysis from a tertiary care center in India

• Main Authors: Purva Kanvinde (Author), Krishnan VP (Author), Parth Ganatra (Author), Archana Swami (Author), Nitin Shah (Author), Mukesh Desai (Author), Bharat Agarwal (Author), Minnie Bodhanwala (Author), Sangeeta Mudaliar (Author)
• Format: Book
• Published: Elsevier, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: BRAF V600 E mutation is present in 50% cases of LCH and is associated with aggressive forms of disease-particularly liver dysfunction in infants and younger children. It is associated with increased mortality due to poorer response to chemotherapy and higher rate of relapse. Though tar...